Helping the retina heal by boosting immune-cell cleanup
Retinal neurovascular protection by boosting efferocytosis
This project aims to see if boosting the retina's ability to clear dead cells can protect vision after injury or in conditions like diabetic retinopathy or retinal vessel occlusion.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project ID | NIH-11182504 on NIH RePORTER |
What this research studies
This research explains how immune cells in the retina (macrophages and microglia) clear away dying cells after ischemic or traumatic injury and whether improving that cleanup can limit nerve and blood vessel damage. The team will use laboratory models to reduce activity of the enzyme HDAC3 in myeloid cells, measure changes in pro-efferocytic proteins such as CD5L and 'don't eat me' signals like CD47, and use RNA sequencing to track molecular changes. Functional and tissue analyses will test whether increased efferocytosis reduces inflammation and preserves retinal structure and function. Results are intended to point toward new treatment strategies that could be tested in patients in the future.
Who could benefit from this research
Good fit: The work is most relevant to people with retinal ischemic or traumatic conditions such as diabetic retinopathy, retinal artery or vein occlusion, or traumatic optic neuropathy.
Not a fit: People whose vision loss is due to inherited retinal degenerations, long-standing end-stage scarring, or causes unrelated to ischemia or trauma are unlikely to benefit from this efferocytosis-focused approach.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that limit vision loss by helping retinal immune cells clear dead cells faster and reduce damaging inflammation.
How similar studies have performed: Approaches that boost efferocytosis have shown promise in preclinical models of atherosclerosis and stroke, but applying them to retinal injury is novel and has not yet been tested in humans.
Where this research is happening
Little Rock, United States
- Univ of Arkansas for Med Scis — Little Rock, United States (Active)
Researchers
- Principal investigator: Fouda, Abdelrahman — Univ of Arkansas for Med Scis
- Study coordinator: Fouda, Abdelrahman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.